Home › Prostate Cancer › New York
Prostate Cancer clinical trials in New York
126 studies for Prostate Cancer are looking for participants at sites in New York.
Cities in New York
- New York City103 studies
- Queens27 studies
- Greenburgh17 studies
- Staten Island16 studies
- New Rochelle16 studies
- The Bronx11 studies
- Buffalo11 studies
- Rochester10 studies
- Syracuse9 studies
- Brooklyn6 studies
- Albany4 studies
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Research Site, New York
- Research Site, New York
RecruitingPhase 1/2
Ages 18 to 130 · All sexes · Updated Oct 5, 2026 · NCT05417594A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
- James J. Peters VA Medical Center, Bronx, NY, The Bronx
RecruitingPhase 2
Ages 18 and older · Men · Updated Oct 5, 2026 · NCT05593497Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients
- Kings County Hopsital Center, Brooklyn
- Queens Cancer Center of Queens Hospital, Jamaica
- Memorial Sloan Kettering at Ralph Lauren Center (Limited Protocol Activities), New York
- and 1 more
Recruiting
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT04751435A Study of Mental Health Care in People With Cancer
- Memorial Sloan Kettering Cancer Center, New York
Recruiting
Ages 65 and older · All sexes · Updated Oct 5, 2026 · NCT06037954A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
- Icahn School of Medicine at Mount Sinai, New York
- and 2 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06465069The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Columbia University Medical Center, New York
- Memorial Sloan Kettering, New York
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
- Roswell Park Cancer Institute, Buffalo
- Memorial Sloan Kettering Commack, Commack
- Guthrie Cortland Memorial Hospital, Cortland
- and 5 more
RecruitingPhase 3
Ages 18 and older · Men · Updated Oct 2, 2026 · NCT06931340Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
- Roswell Park Cancer Institute, Buffalo
- Memorial Sloan Kettering Commack, Commack
- Memorial Sloan Kettering Westchester, Harrison
- and 4 more
RecruitingPhase 3
Ages 18 and older · Men · Updated Oct 2, 2026 · NCT07200830Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
- Roswell Park Cancer Institute, Buffalo
- Mount Sinai Hospital, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06632977Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Queens Hospital Center, Jamaica
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Stony Brook University Medical Center, Stony Brook
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Oct 2, 2026 · NCT05334069A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Roswell Park Cancer Institute IDS, Buffalo
- Memorial Sloan Kettering Hospital, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06172478Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Memorial Sloan Kettering Commack, Commack
- Memorial Sloan Kettering Westchester, Harrison
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- and 3 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT03866382Prostate Cancer Risk Identification in a Multi-Ethnic Cohort: a Prospective US-based Multi-center Validation Study of Proclarix
- Crystal Run Healthcare, Middletown
RecruitingObservational study
Ages 40 to 75 · Men · Updated Sep 28, 2026 · NCT07543757Precision-Based Genomics in Prostate Cancer
- Memorial Sloan Kettering Cancer Center, New York
- Mount Sinai Hospital, New York
- Weill Cornell Medicine, New York
RecruitingObservational study
Ages 18 to 120 · Men · Updated Sep 28, 2026 · NCT04706663A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
- Herbert Irving Comprehensive Cancer Center Columbia University Medical Center, New York
RecruitingPhase 1
Ages 18 and older · Men · Updated Sep 28, 2026 · NCT06095089A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
- Columbia University Medical Center, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07319871Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
- Memorial Sloan Kettering Cancer Center, Long Island City
- Associated Medical Professionals, Syracuse
RecruitingPhase 1/2
Ages 18 and older · Men · Updated Sep 25, 2026 · NCT06800313A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer
- Associated Medical Professionals, Syracuse
RecruitingPhase 2
Ages 18 and older · Men · Updated Sep 25, 2026 · NCT07832292A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- Associated Medical Professionals - Urology ( Site 0081), Syracuse
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06136650Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
- Research Site, New York
RecruitingPhase 1/2
Ages 18 to 130 · Men · Updated Sep 25, 2026 · NCT07181161A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
- Columbia University Medical Center, New York
RecruitingPhase 1
Ages 18 and older · Men · Updated Sep 25, 2026 · NCT07082920This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
- MSK Commack, Commack
- MSKCC-Westchester (500 Westchester Ave.), Harrison
- Integrated Medical Professionals, Lake Success
- and 10 more
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 24, 2026 · NCT07028853Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
- Mount Sinai Hosp Med School, New York
- Associated Med Professionals of NY, Syracuse
- Montefiore Medical Center, The Bronx
RecruitingPhase 2/3
Ages 18 to 100 · Men · Updated Sep 22, 2026 · NCT06780670A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- New York University (NYU) Langone Medical Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07114601A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- Hematology Oncology Association of Central New York, East Syracuse
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 22, 2026 · NCT07213674Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
- Bassett Medical Center, Cooperstown
- Weill Cornell Medicine NY-Presb, New York
- University of Rochester Medical Ctr, Rochester
- and 2 more
RecruitingPhase 3
Ages 18 to 100 · Men · Updated Sep 22, 2026 · NCT06855277A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
- Research Site, New York
- Research Site, Syracuse
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 18, 2026 · NCT06952803Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer
- Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering at Westchester (Limited Protocol Activities), Harrison
- Weill Cornell Medical Center (Data Collection Only), New York
- and 2 more
RecruitingPhase 3
All ages · Men · Updated Sep 18, 2026 · NCT07548164Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
- Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY, New York
RecruitingPhase 2
Ages 18 and older · Men · Updated Sep 17, 2026 · NCT04038502A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- Icahn School of Medicine at Mount Sinai ( Site 0009), New York
- Great Lakes Cancer Care ( Site 0047), Williamsville
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 17, 2026 · NCT06925737A Study of Changes to Prostate Procedures
- Memorial Sloan Kettering Suffolk-Commack (Consent only), Commack
- Memorial Sloan Kettering Westchester (Consent Only), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- and 1 more
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 15, 2026 · NCT06986083PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness
- Memorial Sloan Kettering Cancer Center, New York
RecruitingObservational study
Ages 18 and older · Men · Updated Sep 15, 2026 · NCT04995198MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 2
Ages 18 and older · Men · Updated Sep 15, 2026 · NCT06150417The SUGAR Study; SBRT and Relugolix) for Prostate Cancer
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 2
Ages 18 and older · Men · Updated Sep 14, 2026 · NCT06111781Sacral Neuromodulation for Male Overactive Bladder (MOAB)
- Integrated Medical Professionals, New York
Recruiting
Ages 18 and older · Men · Updated Sep 14, 2026 · NCT06511141Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
- Albany Medical College, Department of Urology, Albany
- Mount Sinai Doctors Urology Faculty Practice, New York
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 11, 2026 · NCT06056830[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate or Salivary Gland Cancer
- Memorial Sloan Kettering Commack (Consent only), Commack
- Memorial Sloan Kettering Westchester (Consent only), Harrison
- Memorial Sloan Kettering Cancer Center, New York
- and 1 more
Recruiting
All ages · Men · Updated Sep 11, 2026 · NCT00588185Transperineal Micro-ultrasound for the Detection of Prostate Cancer During Biopsy
- Roswell Park Cancer Institute, Buffalo
Recruiting
Ages 18 and older · Men · Updated Sep 11, 2026 · NCT07075705Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- Northwell Health Imbert Cancer Center, Bay Shore
- New York-Presbyterian/Brooklyn Methodist Hospital, Brooklyn
- Sands Cancer Center, Canandaigua
- and 19 more
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 10, 2026 · NCT05946213Short Course ADT for High Risk Low/Intermediate Risk ARTERA Prostate Cancer
- NYU Langone Health, New York
RecruitingPhase 2
Ages 18 and older · Men · Updated Sep 3, 2026 · NCT07801664From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.